Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Adolescent TRD
NCT02078817Phase 2Completed
- Sponsor
- University of Minnesota
- Start
- Sep 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by University of Minnesota. Primary endpoint: Number of Responders Measured by Clinical Global Impression (CGI) at 2 weeks. Started Sep 2014; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02078817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078817.